Direct answer
The governance gap is the space between a promising digital health pilot and a service a health system can safely own. Closing it requires named accountability, data governance, clinical safety review, interoperability, financing, procurement, monitoring and a plan for what happens after the pilot team leaves.
Digital health pilots are good at proving that a tool can function under controlled attention. They are less good at proving that a hospital, ministry, payer or care network can absorb the tool into routine work. That distinction matters. A pilot can have enthusiastic users, a clean dashboard and positive survey feedback while still having no permanent owner, no budget line, no integration path and no lifecycle monitoring.
This article is educational analysis for product, policy and implementation teams. It is not clinical, legal, regulatory or procurement advice. Any tool that affects care decisions, patient data, clinical workflow or regulated medical-device claims needs qualified review in the relevant market. The point here is to name the operating questions that determine whether a pilot becomes infrastructure or remains an impressive demonstration.
Pilot success is not the same as infrastructure readiness
A pilot often measures adoption, usability, satisfaction and early workflow fit. Those are useful signals, but they do not answer the infrastructure question. Infrastructure has to keep working after the novelty fades, staff rotate, software versions change, cyber risks evolve and budgets tighten. It has to be supportable by ordinary teams, not only by the founders or grant-funded implementation specialists.
WHO's 2026 toolkit on scaling innovations in public health systems frames scaling as a public-sector stewardship problem, with government actors helping promising innovations move toward sustainable, system-wide adoption. That language is important because it shifts attention away from launch theater and toward ownership. A health system cannot scale a tool it cannot govern.
The recent research literature around health AI and digital health makes a similar point. System-level analyses describe fragmented innovation pathways, fragmented governance, procurement uncertainty, uneven digital maturity and unclear incentives as recurring obstacles. Product teams may experience those as slow sales cycles. Health systems experience them as risk.
Start with ownership, not features
The first governance question is simple: who owns this after the pilot? Ownership is not the same as enthusiasm. A clinical champion can advocate for a tool without having authority to fund it, configure it, audit it or decide whether it should be retired. A vendor can maintain software without owning clinical accountability. A ministry can endorse a strategy without operating every deployment.
Before expansion, the team should document decision rights. Who approves configuration changes? Who decides whether the tool is used in a new facility? Who responds when the tool fails, produces confusing output or creates extra work? Who handles patient complaints, clinician overrides, access requests and security incidents? If those answers are informal, the pilot is not yet infrastructure.
Governance should also include a stop rule. Digital health teams like scale plans; they are less comfortable describing when a tool should pause. A mature plan names the conditions that would trigger review: safety concerns, biased performance, unmanageable workload, poor data quality, integration failure, cyber issues, contract breach or lack of benefit against cost.
Data governance and interoperability decide durability
Most pilots create or move data. That makes data governance central, not optional. Teams should map what data is collected, where it is stored, who can access it, how long it is retained, how consent or legal basis is handled, and how data leaves the system. A diagram that only engineers understand is not enough. Clinical, operational and executive owners need a plain-language map of risk.
Interoperability is the next test. A pilot dashboard may be acceptable for a small trial, but health-system infrastructure usually needs to connect with records, reporting, identity, scheduling, billing, referral or population-health workflows. If the only export is a PDF, a spreadsheet or a manual screenshot, the tool may create another administrative island. That island becomes expensive when the pilot grows.
WHO's digital health governance work emphasizes standards, architecture, strategy and whole-system governance. Product teams should treat that as design input. The question is not whether a product can mention a standard in a sales deck. The question is whether the product can be implemented without forcing every buyer to invent a local workaround.
Evidence must continue after launch
Many pilots stop evidence collection too early. The team measures acceptability, publishes a slide and moves to scale. Infrastructure needs a longer evidence ladder: workflow effects, equity, safety monitoring, service outcomes, staff burden, patient experience, cost, reliability and maintenance. The evidence should match the claim. Do not claim clinical improvement from satisfaction data. Do not claim equity impact without checking who was excluded or harmed.
Regulated or potentially regulated tools need particular care. FDA digital health guidance pages collect current policy documents for medical software and related products, but a guidance page is not a shortcut to authorization. Teams should align public claims, sales material, user interface language and schema metadata with the product's actual status. If a product is not cleared, approved or authorized for a claim, the article, website and demo should not imply that it is.
Monitoring also belongs in the budget. Models drift, integrations break, clinical pathways change, coding systems update and user workarounds appear. If there is no budget for monitoring, there is no real plan for scale. A pilot can be held together by attention; infrastructure needs routine controls.
That monitoring should be owned by people with authority to act. A monthly dashboard is weak if nobody can pause deployment, change training, escalate a safety concern or renegotiate integration support. The practical test is whether the organization can describe the review meeting, the evidence reviewed, the decision options and the person responsible for follow-up. Without that loop, evidence becomes documentation rather than governance.
A readiness checklist before moving beyond pilot
Before expanding, ask ten uncomfortable questions. Is there a named institutional owner? Are clinical, technical and operational decision rights written down? Is the data map current? Does the workflow fit ordinary staffing, not just pilot staffing? Is there an integration plan with the systems of record? Are safety, privacy and equity risks tracked? Are support and training funded? Are performance metrics tied to decisions? Is there a stop or rollback rule? Can the organization explain the tool to patients and staff without exaggeration?
Equity belongs in the same checklist. A pilot may perform well in a digitally mature clinic and fail in a rural service, a low-bandwidth setting or a population that shares devices. Teams should check enrollment drop-off, language access, disability access, offline behavior and who carries extra work when the digital path breaks. Scale that quietly excludes people is not neutral; it moves burden to the patients and workers least able to absorb it.
If several answers are weak, the next step is not necessarily to abandon the product. It may be to redesign the pilot as a governance test. Give the system six weeks to test decision rights, incident handling, data review and workflow ownership. That can be more valuable than adding another feature or recruiting another enthusiastic site.
The healthiest digital health products become quieter as they mature. They stop behaving like a standalone experiment and start fitting into care pathways, evidence routines and accountability structures. That is less exciting than a launch announcement, but it is what makes the difference between a pilot people remember and infrastructure people rely on.
For related analysis, see our guide to the extended WHO digital health strategy and our industry analysis service.
FAQ
What is the governance gap in digital health pilots?
It is the difference between proving a tool can work in a limited setting and proving that a health system can own, monitor, integrate and sustain it.
Should a pilot stop if governance is incomplete?
Not always, but gaps in accountability, data use, clinical safety, procurement or lifecycle monitoring should be named before expansion.
Is this clinical advice?
No. This is educational analysis for product and health-system teams, not medical, regulatory or procurement advice.
Primary sources consulted: WHO's Scaling innovations in public health systems, WHO's digital health governance work, FDA digital health guidance collection, and a 2026 PubMed-indexed study on scaling AI in healthcare.